Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025
Selling, general & admin grows 4.0% year over year
Q4 FY2025 selling, general & admin of $4.24M rose 4.0% year over year. Over 3 fiscal years it compounded at -0.8% a year.
Context
- Selling, general & admin amounted to 31781.3% of revenue in FY2025, up 31707.4 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $485.07M (+2284.8%) for the fiscal year ending Dec 2026, a step up from the +5.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- $4.24M— QoQ
- Last fiscal yearDec 2025
- $20.34M+5.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.34M USD
- Year-over-year change
- +5.8%
- 4-year CAGR
- +1.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.34M | +5.8% |
| FY2024 | 2024-12-31 | 19.23M | +19.8% |
| FY2023 | 2023-12-31 | 16.05M | -22.8% |
| FY2022 | 2022-12-31 | 20.81M | +9.4% |
| FY2021 | 2021-12-31 | 19.01M | — |
Selling, General & Admin vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.8% is the 3rd highest of 9, against a peer median of -8.0%.
- Selling, general & admin amounts to 31781.3% of revenue for CNTB, versus a peer median of 1042.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.33M USD | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $24.75M USD | -6.4% | -9.4% | 347.5% | |
IMAImageneBio Inc | LTM Mar 2026 | $21.2M USD | -9.1% | -2.3% | — |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M USD | +8.2% | -0.8% | — |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M USD | -41.8% | +90.0% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| LTM Mar 2026 | $8.11M USD | +9.0% | +0.2% | — | |
| Peer median (excluding CNTB) | — | -8.0% | -1.5% | 1042.0% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.